A 12-week proof of concept study of GL0034 in obese adults with type 2 diabetes, non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 27 Jun 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Utreglutide (Primary)
Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
Focus Proof of concept; Therapeutic Use

27 Jun 2023 New trial record
24 Jun 2023 According to a Sun Pharmaceutical Industries Media Release, Phase 2 clinical trials anticipated to commence in 2023.
24 Jun 2023 According to a Sun Pharmaceutical Industries Media Release, this study will begin enrollment during 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com